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Background 
Outpatient parenteral antimicrobial therapy (OPAT) is defined as the 
administration of parenteral antimicrobials in at least two doses given on different 
days and without a hospitalization between.1 Rather than a patient being required 
to remain in a hospital solely to receive antimicrobial therapy after medical 
discharge, he or she can complete a portion of the therapy as an outpatient. The 
ability to discharge a patient on intravenous (IV) antimicrobial therapy has been 
shown to potentially reduce the high costs associated with chronic administration 
of antibiotics,2 increase the patient’s quality of life by granting improved flexibility 
and convenience, and reduce the likelihood that the patient will acquire a 
nosocomial infection.2 As a result, OPAT has grown at a breakneck pace since its 
inception in the 1970s, and projections of its market share predict that it will soon 
reach the multibillion-dollar-a-year threshold.1  
Interprofessional collaboration and careful selection of patients designated 
to receive OPAT are critical to ensuring successful therapy. Beyond the clinical 
expertise offered by infectious diseases (ID) physicians, coordination of social 
support and third-party authorizations between case management and pharmacy 
contribute significantly to a patient’s ability to receive appropriate therapy. In some 
cases, the provision of home-based OPAT services can prevent an otherwise 
medically unnecessary stay at a subacute rehabilitation facility to receive IV 
antimicrobials for patients without reliable transportation to an infusion center. 
Additionally, in patients for whom adequate monitoring and follow-up cannot be 
guaranteed, complications related to vascular access devices and adverse drug 
reactions can lead to significant harm.3 Both social and medical evaluations should 
therefore be integral in the process of identifying patients appropriate to receive 
OPAT. 
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Furthermore, input from pharmacists to assist in the appropriate selection 
of antimicrobials and of durations of therapies has the potential to stem the rising 
tide of resistant microorganisms. The interventions related to spectrum and duration 
can lead to vastly reduced rates of adverse effects due to unnecessary antimicrobial 
use and can also reduce the likelihood that the patient may encounter an infection 
caused by a resistant organism later in life.4 Additionally, it may reduce the rate of 
multidrug-resistant organisms, which is especially critical for patients who must be 
admitted but are also most at risk. Through appropriate recommendations related 
to the spectrum and duration of therapy, selection of resistant microorganisms can 
be minimized, which partially mitigates these risks. 
In November 2016 at a community hospital, a dedicated pharmacist was 
hired to continue to build a formal OPAT program for all patients discharged on IV 
antimicrobials under the care of the ID physician group. Through a collaborative-
practice agreement, the pharmacist’s responsibilities upon consultation were to 
evaluate and create a plan with recommendations related to antimicrobial selection 
(including drug, dose, route, frequency, and duration) as well as monitoring 
parameters. The pharmacist also provided patient education and assistance to case 
managers involved with disposition planning. Upon patients’ discharge from the 
hospital, the pharmacist continued weekly monitoring throughout the duration of 
therapy of all patients who received such consultative services during their inpatient 
stay. Because of the relatively new nature of this OPAT program and the number 
of “good catch” events—in which a potential medical error related to the therapy 
or monitoring was prevented—observed since the program’s formal inception, this 
study sought to examine the impact of an OPAT program for those patients 
receiving OPAT at hospital discharge.  
Methods 
This was a retrospective observational cohort study examining patients with 
an order for an IV antibiotic following discharge from a community hospital within 
the period of December 1, 2016, to May 31, 2017. Patients who received OPAT 
consults during their index hospital stay were compared to those patients who did 
not receive consults in the same period. Only adult patients were included in this 
study. Patients residing in a nursing home or long-term care facility prior to 
admission and those also receiving oral antimicrobials were excluded from the 
analysis. The primary objective was the proportion of patients in each group 
readmitted within 30 days of discharge and OPAT initiation, which was stratified 
by the reason for readmission (ID process, adverse drug event, or unrelated reason). 
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Baseline demographic information collected included age, sex, weight, and length 
of stay prior to discharge. Type of infection, antimicrobial selection (including 
agents with antipseudomonal activity or requiring therapeutic drug monitoring), 
duration of treatment, and disposition at hospital discharge were also collected from 
the electronic medical record. As avoiding unnecessary short-term acute 
rehabilitation (SAR) stays in cases where therapy can be altered and coordinated 
with home healthcare is one potential benefit of OPAT, change in disposition from 
admission to discharge was also collected.  
Statistical Analysis 
The Fisher’s exact test and chi-square analyses were utilized as appropriate 
for nominal endpoints including the 30-day readmission rate, use of each 
antimicrobial class, and use of agents with a high risk for a Clostridioides difficile 
infection, such as ceftriaxone, or requiring therapeutic drug monitoring. The 
Wilcoxon rank-sum test was utilized to determine the significance of differences in 
length of stay and duration of therapy. Statistical Package for the Social Sciences 
(SPSS) software was utilized for these analyses. All other variables and baseline 
demographic information were described utilizing descriptive statistics. 
Results 
No statistically significant differences between groups were seen in terms 
of demographic information (Table 1).  
 
 OPAT Consult 
(n = 95) 
No OPAT 
Consult 
(n = 22) 
p Value 
Median Age (IQR) 61 (21) 63 (26) 0.503 
Sex (%) 
     M 
     F 
 
42 (44) 
53 (56) 
 
6 (27) 
16 (73) 
 
0.146 
Median Weight 
(IQR) 
91 kg  
(35 kg) 
79 kg  
(41 kg) 
0.085 
Median Index LOS 
(IQR) 
6 (5) 7 (8) 0.313 
Table 1. Patient Demographics 
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No statistically significant difference between the readmission rates of the 
OPAT consult group and the non-consult group was observed; however, the rate 
for the former was less than half of the latter, numerically (14.73% vs. 31.82%, p = 
0.07). Additionally, the proportion of patients requiring a change in disposition did 
not vary significantly between groups (Table 2), with 39 (41%) patients with a 
consult and 12 (55%) patients without a consult being discharged to a SAR center 
or extended-care facility (ECF; p = 0.252). Bacteremia associated with various 
sources of infection was the most common type of infection requiring IV therapy 
in both groups, constituting 35% of patients in the OPAT consult group and 59% 
of the patients without a consult. Differences in provider type and indication for 
therapy between groups were statistically significant (p < 0.0001; 3 x 10–12). The 
median total days of therapy for patients with a consult was 24, in comparison to 
25 in the non-consult group (p = 0.095).  
 
 OPAT Consult 
(n = 95) 
No OPAT 
Consult  
(n = 22) 
p Value 
Disposition Change 39 (41%) 12 (55%) 0.252 
Indication for Therapy 
     Empyema 
     Osteomyelitis 
     Bacteremia 
     Intra-Abdominal Infection 
     Skin and Soft Tissue 
Infection (SSTI) 
     Other 
 
7 
11 
33 
10 
 
25 
9 
 
2 
2 
13 
3 
 
0 
2 
3 x 10–12 
 
Primary Provider Type 
     Pulmonary 
     Cardiology 
     Surgery 
     Internal Medicine 
     Oncology 
 
5  
10  
25  
52  
3  
 
7  
1 
4 
8 
2 
0.000095 
 
Median Days of Therapy 
(IQR) 
24 (19) 25 (17) 0.095 
Table 2. Disposition Change, Therapy Indication, and Provider Type, All Patients 
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The most significantly differing trends between groups were evident in 
prescribing practices. The usage of antipseudomonal coverage was significantly 
lower in the OPAT consult group (39.58% vs. 86.36%, p = 0.00006). Additionally, 
utilization of ceftriaxone, known for its potential to predispose patients to C. 
difficile infections, was also significantly lower in the OPAT consult group (9.47% 
vs. 45.45%, p = 0.00004). Differences in other key antibiotics that serve as 
stewardship targets were also seen with piperacillin-tazobactam, cefepime, and 
vancomycin (Table 3). Also of interest, patients without an OPAT consult who 
were discharged to a SAR center or ECF were significantly more likely to have 
been prescribed agents requiring therapeutic drug monitoring (100% vs. 59.56%, p 
= 0.038) and to have later required readmission (54.55% vs. 16.22%, p = 0.001). 
 
Drug Choice      OPAT Consult  
(n = 95) 
No OPAT 
Consult 
(n = 22) 
p Value 
Ampicillin 5 2 0.495 
Ampicillin-Sulbactam 12 2 0.645 
Piperacillin-Tazobactam 13 11 0.0001 
Cefazolin 15 3 0.801 
Ceftazidime 1 0 0.203 
Ceftriaxone 9 10 0.00004 
Cefuroxime 1 1 0.255 
Cefepime 10 7 0.011 
Meropenem 8 5 0.054 
Ertapenem 4 1 0.944 
Gentamicin 6 5 0.017 
Tobramycin 0 4 0.0002 
Vancomycin 39 19 0.0001 
Linezolid 0 2 0.023 
Daptomycin 1 0 0.213 
Metronidazole 2 5 0.0002 
Clindamycin 2 2 0.104 
Fluconazole 2 2 0.104 
Antipseudomonal 
Agents 
37 19 0.00006 
Table 3. Therapeutic Drug Choice, All Patients 
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Readmitted Subgroup 
When examining readmitted patients as a subgroup, several differences 
between those receiving a consult and those without were seen (Table 4). 
Significant differences in the indications for therapy (p = 0.009) were seen in this 
population, with bacteremia and SSTIs as the most common infection types in the 
OPAT consult (71%) and non-consult (43%) groups, respectively. Additionally, a 
trend was seen showing that patients in this subgroup without a consult were more 
likely to have experienced a change in disposition (85.71% vs. 42.86%, p = 0.061). 
 
 
 OPAT Consult  
(n = 14) 
No OPAT Consult  
(n = 7) 
p Value 
Median Age (IQR) 61 (16) 64 (26) 0.711 
Sex 
     Male 
     Female 
 
8  
6  
 
5  
2  
 
0.525 
Indication for Therapy 
     Osteomyelitis 
     Bacteremia 
     Intra-Abdominal 
Infection 
     Skin and Soft Tissue 
Infection (SSTI) 
     Other 
 
2 
3 
 
2 
 
6 
1 
 
1 
5 
 
1 
 
0 
0 
0.009 
 
Median Index Length of 
Stay in Days (IQR) 
6 (2) 7 (3) 0.352 
Median Days to 
Readmission (IQR) 
12 (14) 9 (6) 0.368 
Disposition at Discharge 
     Home 
     ECF or SAR 
 
 
8 
6 
 
 
1 
6 
 
0.061 
 
Disposition Change 6 (43%) 6 (86%) 0.061 
Median Total Days of 28 (24) 28 (27) 0.190 
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Therapy (IQR) 
Reason for Readmission 
     ID Process 
     Adverse Drug Event 
     Unrelated Process 
 
 
2 
3 
9 
 
 
3 
1 
3 
 
0.216 
 
Table 4. Readmitted Patients 
 
Discussion 
No statistical significance in terms of the primary objective (30-day 
readmission rate) was seen in the study; however, the more than twofold difference 
in readmission rate can certainly be seen as clinically significant. The readmission 
rate of 14.74% was also similar to the 21.5% readmission rate reported by another 
study, which somewhat adds to the confidence with which the results from this 
study can be interpreted.5 
Considerable improvements in antimicrobial stewardship were seen when 
comparing the group of patients receiving a consult to those who did not. This 
enhancement in stewardship was primarily via reduced utilization of 
antipseudomonal coverage, vancomycin, and ceftriaxone, which demonstrated the 
key role that such programs can have on selecting therapy with an appropriately 
narrow spectrum. One way by which OPAT can reduce costs and improve patient 
outcomes comes via the involvement of ID specialists to improve the selection of 
appropriately narrow-spectrum antimicrobials. By avoiding the use of overly broad 
coverage, the risk of off-target eradication of the gut microbiome and subsequent 
development of a C. difficile infection can be significantly reduced. Beyond the 
clinical impact of this variety of infectious diarrhea, C. difficile’s propensity for 
toxin production leads to 4.8 billion dollars in additional costs to hospitals in the 
United States annually.6 For example, unnecessary use of ceftriaxone, a 
cephalosporin utilized for a variety of infections, has become one of many potential 
targets for antimicrobial stewardship programs because of its common use and 
propensity for causing this type of infection.6,7 It is imperative that therapies be 
selected appropriately to cover only the types of microorganisms likely to be 
causing the patient’s infection and that therapies be narrowed when culture and 
susceptibility data are available. This is a major point of potential impact for 
pharmacist-led OPAT services. 
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The difference in readmissions seen for patients without a consult sent to a 
SAR center or ECF may hint at a potential positive influence seen with the inclusion 
of a dedicated ID clinical pharmacy specialist to coordinate careful monitoring 
during the course of OPAT. Especially when utilizing agents requiring therapeutic 
drug monitoring, such as vancomycin or aminoglycosides, the potential for 
significant adverse effects is considerable. Additionally, poor availability of lab 
data during the course of OPAT has been noted to be a significant risk factor for 
readmission, which may partially explain the difference seen here.8 The potentially 
increased debility or acuity of patients more likely to be sent to a SAR center or 
ECF, in comparison to a patient able to be sent home, could have also contributed 
to this observation; however, an increase in readmission for patients discharged to 
these facilities after receiving a consult was not observed. 
The need for appropriate monitoring and communication between 
healthcare systems should be given careful consideration prior to the 
implementation of OPAT. One report noted that 26% of sites surveyed had a team 
specifically designated to handle OPAT cases.5 A survey of practitioners involved 
in an OPAT service indicated that up to 70% had seen such therapy implemented 
without a consult from an ID specialist, and another study showed that the addition 
of a pharmacist or ID physician or pharmacist to an OPAT team raised adherence 
to monitoring by 32% and 64%, respectively.9,10 One study showed that cases 
reviewed by an ID physician led to changes in therapy from parenteral to oral agents 
in 27%–40% of cases.9 This shows the value of a dedicated OPAT team’s ability to 
improve patient care via appropriate selection of antimicrobial therapy from a 
therapeutic perspective, which often reduces costs.  
Although poor communication can be a barrier to the success of OPAT, 
adverse effects have been cited as the primary reason for OPAT discontinuation or 
therapy modification in 3%–5% of cases.9 The rate of readmission, potentially 
requiring a change in therapy, in this study for adverse events in the OPAT and 
non-OPAT groups was similar to this cited figure, at 3.2% and 4.5%, respectively. 
A survey of ID physicians conducted in 2012 showed that only 22% of the OPAT 
programs in which they worked had a way to track medication errors, “near 
misses,” or adverse events.5 Additionally, it is of utmost importance that patients 
who are to receive OPAT be carefully selected to ensure that they have appropriate 
social and financial support to receive therapy at home, at an infusion center, or at 
another location. The potential ramifications for patients inappropriately selected 
for outpatient therapy include both clinical decompensation as well as the potential 
for enhanced resistance by the responsible pathogen due to incomplete eradication.  
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Several limitations should be considered when interpreting the results of 
this study. The small sample size and timing of the study period at the advent of the 
program could have affected the results. This trend could possibly have been due 
to the novelty of the new program or to increased provider confidence in the 
utilization of a formalized OPAT program able to more consistently offer improved 
monitoring and follow-up after discharge. The lack of assessments related to 
appropriateness of therapy, comorbidities, severity of infection, and causative 
pathogen limits the generalizability of these findings.  
As OPAT services continue to expand in the United States, further 
investigations utilizing larger sample sizes and examining shifting trends in patient 
outcomes should be conducted in order to further assess the value of the program 
and monitor for potential quality-improvement opportunities. Furthermore, patient 
and provider satisfaction data could be included to better assess the improvements 
in quality of life and perception of value associated with the program. This study 
suggests a potential indication for the potential patient-care improvements related 
to improved patient outcomes that OPAT services can offer to patients. 
BUTLER JOURNAL OF UNDERGRADUATE RESEARCH, VOLUME 6 
 
25 
 
 
 
 
References 
1. Tice AD, Rehm SJ, Dalovisio JR. Practice guidelines for outpatient parenteral 
antimicrobial therapy. Clin Infect Dis. 2004;38:1661-1672. 
doi:10.1086/420939. 
2. Ruh CA, Parameswaran GI, Wojciechowski AL, Mergenhagen KA. Outcomes 
and pharmacoeconomic analysis of a home intravenous antibiotic infusion 
program in veterans. Clin Ther. 2015;37(11):2527-2535. 
doi:10.1016/j.clinthera.2015.09.009. 
3. Chung EK, Beller CB, Muloma EW, et al. Development and implementation of 
a pharmacist-managed outpatient parenteral antimicrobial therapy program. Am 
J Health Syst Pharm. 2016;73(1):e24-e33. doi:10.2146/ajhp150201. 
4. Diaz Granados CA. Prospective audit for antimicrobial stewardship in intensive 
care: impact on resistance and clinical outcomes. Am J Infect Control. 
2012;40(6):526-529. doi:10.101/j.ajic.2011.07.011. 
5. Lane MA, Marschall J, Beekmann SE, et al. Outpatient parenteral antimicrobial 
therapy practices among adult infectious disease physicians. Infect Control 
Hosp Epidemiol. 2014;35(7):839-844. doi:10.1086/676859. 
6. Scott II RD. The direct medical costs of healthcare-associated infections in U.S. 
hospitals and the benefits of prevention 2009. Division of Healthcare Quality 
Promotion National Center for Preparedness, Detection, and Control of 
Infectious Diseases, Centers for Disease Control and Prevention. 
7. Ceftriaxone [package insert]. Indianapolis, IN: Hoffmann La Roche; 1984. 
8. Huck D, Ginsberg JP, Gordon SM, et al. Association of laboratory test result 
availability and rehospitalizations in an outpatient parenteral antimicrobial 
therapy programme. J Antimicrob Chemother. 2014;69(1):228-233. 
doi:10.1093/jac/dkt303. 
9. Muldoon EG, Snydman DR, Penland EC, Allison GM. Are we ready for an 
outpatient parenteral antimicrobial therapy bundle? A critical appraisal of the 
evidence. Clin Infect Dis. 2013;57(3):419-424. doi:10.1093/cid/cit955. 
10. Shah PJ, Bergman SJ, Graham DR. Monitoring of outpatient parenteral 
antimicrobial therapy and implementation of clinical pharmacy services at a 
community hospital infusion unit. J Pharm Pract. 2014;28(5):462-468. 
doi:10.1177/0897190014544786. 
  
